Form 4: Cytokinetics Executive Fady Ibraham Malik Reports Stock Transactions
SEC Form 4 Filing
EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, reports the acquisition and disposal of company stock and stock options on October 1, 2024.
Summary
- On October 1, 2024, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., reported transactions involving the company's common stock and non-qualified stock options.
- Malik disposed of 2,000 shares of common stock at a price of $52.11.
- Malik exercised 5,300 non-qualified stock options with an exercise price of $7.96.
- Malik acquired 5,300 shares of common stock upon exercising the options at $7.96 per share.
- Malik disposed of 5,300 shares of common stock at a price of $52.09.
- Following these transactions, Malik directly owns 118,920 shares of Cytokinetics common stock and 26,500 non-qualified stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders may be interested in the transactions of company executives as an indicator of their confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date the non-qualified stock options were granted. |
| 10/01/2024 | Date of the reported transactions: stock disposal, option exercise, and stock disposal. |
| 02/26/2025 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.